SMMT Stock Overview
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Summit Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.14 |
| 52 Week High | US$5.78 |
| 52 Week Low | US$0.66 |
| Beta | -1.0 |
| 1 Month Change | -35.79% |
| 3 Month Change | 204.85% |
| 1 Year Change | 52.43% |
| 3 Year Change | 88.02% |
| 5 Year Change | -70.38% |
| Change since IPO | -69.48% |
Recent News & Updates
Recent updates
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
Dec 29
Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation
Apr 29Summit Therapeutics - Disappointing Data But Not An Outright Failure
Dec 23Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator
Jun 22Summit Therapeutics to join Russell 3000 Index
Jun 08Shareholder Returns
| SMMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | -0.8% | 1.7% |
| 1Y | 52.4% | 4.4% | -9.6% |
Return vs Industry: SMMT exceeded the US Biotechs industry which returned 4.5% over the past year.
Return vs Market: SMMT exceeded the US Market which returned -8.5% over the past year.
Price Volatility
| SMMT volatility | |
|---|---|
| SMMT Average Weekly Movement | 61.8% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SMMT is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 62% a week.
Volatility Over Time: SMMT's weekly volatility has increased from 34% to 62% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 108 | Bob Duggan | https://www.summittxinc.com |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company’s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
Summit Therapeutics Inc. Fundamentals Summary
| SMMT fundamental statistics | |
|---|---|
| Market Cap | US$694.70m |
| Earnings (TTM) | -US$86.65m |
| Revenue (TTM) | US$956.00k |
726.7x
P/S Ratio-8.0x
P/E RatioIs SMMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMMT income statement (TTM) | |
|---|---|
| Revenue | US$956.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$956.00k |
| Other Expenses | US$87.61m |
| Earnings | -US$86.65m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -9,064.02% |
| Debt/Equity Ratio | 0% |
How did SMMT perform over the long term?
See historical performance and comparison